Search Results - "Mendez Vidal, Maria Jose"

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms by Grünwald, Viktor, Powles, Thomas, Eto, Masatoshi, Kopyltsov, Evgeny, Rha, Sun Young, Porta, Camillo, Motzer, Robert, Hutson, Thomas E, Méndez-Vidal, María José, Hong, Sung-Hoo, Winquist, Eric, Goh, Jeffrey C, Maroto, Pablo, Buchler, Tomas, Takagi, Toshio, Burgents, Joseph E, Perini, Rodolfo, He, Cixin, Okpara, Chinyere E, McKenzie, Jodi, Choueiri, Toni K

“…The phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients…”
Get full text

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma by Méndez-Vidal, María José, Molina, Áurea, Anido, Urbano, Chirivella, Isabel, Etxaniz, Olatz, Fernández-Parra, Eva, Guix, Marta, Hernández, Carolina, Lambea, Julio, Montesa, Álvaro, Pinto, Álvaro, Ros, Silverio, Gallardo, Enrique

“…Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and…”
Get full text

Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE by Puente, Javier, Anido, Urbano, Climent, Miguel Ángel, Gonzalez-Billalabeitia, Enrique, Lainez, Nuria, Lambea, Julio, Maroto, José Pablo, Mendez-Vidal, Maria Jose, Montesa, Álvaro, Rodriguez, Angel, Zambrana, Curro, González-del-Alba, Aránzazu

“…Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have…”
Get full text

SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023) by Arranz Arija, José Angel, del Muro, Xavier García, Caro, Raquel Luque, Méndez-Vidal, María José, Pérez-Valderrama, Begoña, Aparicio, Jorge, Climent Durán, Miguel Ángel, Caballero Díaz, Cristina, Durán, Ignacio, González-Billalabeitia, Enrique

“…Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent,…”
Get full text

SEOM SOGUG clinical guideline for treatment of kidney cancer (2022) by Méndez-Vidal, María José, Lázaro Quintela, Martin, Lainez-Milagro, Nuria, Perez-Valderrama, Begoña, Suárez Rodriguez, Cristina, Arranz Arija, José Ángel, Peláez Fernández, Ignacio, Gallardo Díaz, Enrique, Lambea Sorrosal, Julio, González-del-Alba, Aránzazu

“…Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of…”
Get full text

Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study by Juan Fita, María José, Anido Herranz, Urbano, Mendez-Vidal, María José, Gironés-Sarrió, Regina, Muñoz-Langa, José, Sepúlveda-Sánchez, Juan, Mellado, Begoña, Alvarez-Fernandez, Carlos, Heras López, Lucía, López-Guerrero, José Antonio, García-Casado, Zaida, Calatrava, Ana, Ángel Climent, Miguel

“…The SOGUG-IMANOL trial was a phase 2, uncontrolled, Spanish multicenter study to assess the effect of maintenance treatment with olaparib on radiographic…”
Get full text

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer by Lorente, David, Castro, Elena, Lozano, Rebeca, Puente, Javier, Romero-Laorden, Nuria, Rodríguez-Vida, Alejo, Lainez, Nuria, Villatoro, Rosa, Llácer, Casilda, Cattrini, Carlo, Hernández, Amaia, Domenech, Montserrat, Zambrana, Francisco, Almagro, Elena, Luque, Raquel, Martinez, Esther, López-Campos, Fernando, Gonzalez, Belen, Méndez-Vidal, Maria Jose, Medina, Ana, Piulats, Josep Maria, Olmos, David

Get full text

Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer by Perez-Navarro, Enrique, Conteduca, Vincenza, Funes, Juan M, Dominguez, Jose I, Martin-Serrano, Miguel, Cremaschi, Paolo, Fernandez-Perez, Maria Piedad, Gordoa, Teresa Alonso, Font, Albert, Vázquez-Estévez, Sergio, González-Del-Alba, Aránzazu, Wetterskog, Daniel, Mellado, Begona, Fernandez-Calvo, Ovidio, Méndez-Vidal, María José, Climent, Miguel Angel, Duran, Ignacio, Gallardo, Enrique, Rodriguez Sanchez, Angel, Santander, Carmen, Sáez, Maria Isabel, Puente, Javier, Tudela, Julian, Marinas, Cecilia, López-Andreo, María Jose, Castellano, Daniel, Attard, Gerhardt, Grande, Enrique, Rosino, Antonio, Botia, Juan A, Palma-Mendez, Jose, De Giorgi, Ugo, Gonzalez-Billalabeitia, Enrique

“…The prognosis for patients with metastatic castration-resistant prostate cancer (mCRPC) varies, being influenced by blood-related factors such as…”
Get full text

Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib by de Velasco, Guillermo, Alonso-Gordoa, Teresa, Rodríguez-Vida, Alejo, Anguera, Georgia, Campayo, Marc, Pinto, Álvaro, Ortega, Esther Martínez, Gallardo, Enrique, Núñez, Natalia Fernández, García-Carbonero, Iciar, Reig, Oscar, Méndez-Vidal, María José, Fernández-Calvo, Ovidio, Cassinello, Natalia Vidal, Torregrosa, Dolores, López-Martín, Ana, Rosero, Adriana, Valiente, Patricia G., de España, Carmen Garcías, Climent, Miguel A., Santasusana, Montserrat Domenech, Sánchez, Ángel Rodríguez, González, Isabel Chirivella, Afonso, Ruth, García del Muro, Xavier, Casinello, Javier, Fernández-Parra, Eva M., García Sánchez, Lourdes, Afonso, Javier, Polo, Susana Hernando, Asensio, Úrsula

“…The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI)…”
Get full text

Correlation between time to PSA progression (TTPP), radiographic progression-free survival (rPFS) and overall survival (OS) in first-line abiraterone/enzalutamide (Abi/Enza) and docetaxel (Doc) treated patients in a prospective cohort study by Lorente, David, Castro, Elena, Lozano, Rebeca, Puente, Javier, Romero-Laorden, Nuria, Morales-Barrera, Rafael, Rodriguez Vida, Alejo, Sáez, M Isabel, Mendez-Vidal, Maria Jose, Fernandez, Eva, Almagro, Elena, Hernandez, Amaia, Hernando Polo, Susana, Pérez-Valderrama, Begoña, López-Campos, Fernando, Llacer Perez, Casilda, Montesa, A., Lainez, Nuria, Piulats, Josep M., Olmos, David

“…Abstract only 267 Background: Abiraterone, enzalutamide and docetaxel represent first-line (1L) treatment options in mCRPC. A significant correlation between…”
Get full text

Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study by Lainez, Nuria, García-Donas, Jesús, Esteban, Emilio, Puente, Javier, Sáez, M Isabel, Gallardo, Enrique, Pinto-Marín, Álvaro, Vázquez-Estévez, Sergio, León, Luis, García-Carbonero, Icíar, Suárez-Rodríguez, Cristina, Molins, Carmen, Climent-Duran, Miguel A, Lázaro-Quintela, Martín, González Del Alba, Aranzazu, Méndez-Vidal, María José, Chirivella, Isabel, Afonso, Francisco J, López-Brea, Marta, Sala-González, Nuria, Domenech, Montserrat, Basterretxea, Laura, Santander-Lobera, Carmen, Gil-Arnáiz, Irene, Fernández, Ovidio, Caballero-Díaz, Cristina, Mellado, Begoña, Marrupe, David, García-Sánchez, José, Sánchez-Escribano, Ricardo, Fernández Parra, Eva, Villa Guzmán, José C, Martínez-Ortega, Esther, Belén González, María, Morán, Marina, Suarez-Paniagua, Beatriz, Lecumberri, María J, Castellano, Daniel

“…The impact of such recommendations after their implementation of guidelines has not usually been evaluated. Herein, we assessed the impact and compliance with…”
Get full text

Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer by Jiménez-Vacas, Juan M, Gómez-Gómez, Enrique, Montero-Hidalgo, Antonio J, Herrero-Aguayo, Vicente, L-López, Fernando, Sánchez-Sánchez, Rafael, Guler, Ipek, Blanca, Ana, Méndez-Vidal, María José, Carrasco, Julia, Lopez-Miranda, José, Requena-Tapia, María J, Castaño, Justo P, Gahete, Manuel D, Luque, Raúl M

“…Recent data suggested that plasma Ghrelin O-Acyl Transferase enzyme (GOAT) levels could represent a new diagnostic biomarker for prostate cancer (PCa). In this…”
Get full text

A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients by Alsina, Maria, Rivera, Fernando, Ramos, Francisco Javier, Galán, Maica, López, Rafael, García-Alfonso, Pilar, Alés-Martinez, José Enrique, Queralt, Bernardo, Antón, Antonio, Carrato, Alfredo, Grávalos, Cristina, Méndez-Vidal, Maria José, López, Carlos, de Mena, Inmaculada Ruiz, Tabernero, Josep, Giralt, Jordi, Aranda, Enrique

“…Background Pre-operative chemoradiotherapy using a 5-fluorouracil (5-FU)/cisplatin backbone is widely used to improve surgical outcomes in locoregional…”
Get full text

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01) by García-Donas, Jesús, Leon, Luis Angel, Esteban, Emilio, Vidal-Mendez, Maria Jose, Arranz, Jose Angel, Garcia del Muro, Xavier, Basterretxea, Laura, González del Alba, Aranzazu, Climent, Miguel Angel, Virizuela, Juan Antonio, Álvarez, Carlos, Sepúlveda, Juan, Anido, Urbano, López, Carlos, Ortiz-Morales, Maria Jose, Pérez, Xavier, Rodriguez-Antona, Cristina, Rodriguez-Moreno, Juan Francisco, Hernando, Susana, Castellano, Daniel

“…Abstract Background Markers able to predict the response to antiangiogenics in metastatic clear cell renal cell carcinoma (ccRCC) are not available. The…”
Get full text

Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer by González-Billalabeitia, Enrique, Sepúlveda, Juan Manuel, Maroto, Pablo, Aparicio, Jorge, Arranz, Jose Angel, Esteban, Emilio, Gironés, Regina, López-Brea, Marta, Mendez-Vidal, María José, Pinto, Alvaro, Sastre, Javier, de Prado, Diego Soto, Terrasa, Josefa, Vázquez, Sergio, Powles, Thomas, Beyer, Jörg, Castellano, Daniel, del Muro, Xavier García

“…Abstract Background High-dose chemotherapy (HDCT) has been studied in several clinical scenarios in advanced germ cell cancer (GCC). Objective To establish a…”
Get full text

Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain by Puente, Javier, Pinto, Alvaro, Mendez-Vidal, Maria José, García Del Muro, Xavier, Maroto, Pablo, Vazquez, Sergio, Luque-Caro, Raquel, Anido, Urbano, Strunz-McKendry, Torsten, Upadhyay, Anil, Montes, Jose, Ortiz Nuñez, Aurora, González Portela, Judit, Castellano, Daniel

“…Real-world evidence on locally advanced or metastatic urothelial carcinoma (la/mUC) management in Spain is limited. This study describes patient…”
Get full text

Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study by Motzer, Robert, Porta, Camillo, Alekseev, Boris, Rha, Sun Young, Choueiri, Toni K, Mendez-Vidal, Maria Jose, Hong, Sung-Hoo, Kapoor, Anil, Goh, Jeffrey C, Eto, Masatoshi, Bennett, Lee, Wang, Jinyi, Pan, Jie Janice, Saretsky, Todd L, Perini, Rodolfo F, He, Cixin Steven, Mody, Kalgi, Cella, David

“…Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib…”
Get full text

Phase II trial evaluating olaparib maintenance in patients with metastatic castration resistant prostate cancer (mCRPC) after docetaxel treatment, reaching partial or stable response: SOGUG-IMANOL study by Juan FITA, Maria Jose, Anido Herranz, Urbano, Mendez Vidal, Maria Jose, Gironés, Regina, Mellado-Gonzalez, Begoña, Sepulveda Sánchez, José Manuel, Alvarez-Fernandez, Carlos, Climent, Miguel Ángel, Heras, Lucia

“…168 Background: Prostate cancer is the second most common cancer in men. A number of important systemic therapies have been developed to treat mCRPC and now…”
Get full text

Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO) by Suárez, Cristina, Larkin, James M G, Patel, Poulam, Valderrama, Begoña P, Rodriguez-Vida, Alejo, Glen, Hilary, Thistlethwaite, Fiona, Ralph, Christy, Srinivasan, Gopalakrishnan, Mendez-Vidal, Maria Jose, Hartmaier, Ryan, Markovets, Aleksandra, Prendergast, Aaron, Szabados, Bernadett, Mousa, Kelly, Powles, Thomas

“…Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal…”
Get full text

Real-world treatment patterns, survival outcomes, and health care resource utilization (HCRU) for locally advanced or metastatic urothelial carcinoma (la/mUC) in Spain by Puente, Javier, Pinto, Alvaro, Mendez Vidal, Maria Jose, Garcia del Muro, Xavier, Maroto-Rey, Pablo, Vazquez-Estevez, Sergio, Luque, Raquel, Anido, Urbano, Strunz-McKendry, Torsten, Upadhyay, Anil, Montes, Jose, Ortiz Nuñez, Aurora, González Portela, Judit, Castellano, Daniel

“…463 Background: Real-world evidence on la/mUC management in Europe is limited. This study describes patient (pt) characteristics, treatment patterns, survival,…”
Get full text